MCID: OBS001
MIFTS: 53

Obstructive Jaundice

Categories: Gastrointestinal diseases, Genetic diseases

Aliases & Classifications for Obstructive Jaundice

MalaCards integrated aliases for Obstructive Jaundice:

Name: Obstructive Jaundice 12 15 17
Jaundice, Obstructive 45 74
Obstructive Hyperbilirubinemia 12
Cholestatic Jaundice Syndrome 12
Cholestatic Jaundice 12
Jaundice Obstructive 56
Jaundice Cholestatic 56

Classifications:



External Ids:

Disease Ontology 12 DOID:13603
MeSH 45 D041781
NCIt 51 C34742
SNOMED-CT 69 44018007 59848001
UMLS 74 C0022354

Summaries for Obstructive Jaundice

MalaCards based summary : Obstructive Jaundice, also known as jaundice, obstructive, is related to hepatitis and autoimmune hepatitis, and has symptoms including icterus and jaundice (not of newborn). An important gene associated with Obstructive Jaundice is ALPP (Alkaline Phosphatase, Placental), and among its related pathways/superpathways are Immune response IFN alpha/beta signaling pathway and IL-1 Family Signaling Pathways. The drugs Lactulose and Ceftriaxone have been mentioned in the context of this disorder. Affiliated tissues include liver, pancreas and kidney, and related phenotypes are growth/size/body region and homeostasis/metabolism

Related Diseases for Obstructive Jaundice

Diseases in the Obstructive Jaundice family:

Jaundice, Familial Obstructive, of Infancy

Diseases related to Obstructive Jaundice via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 542)
# Related Disease Score Top Affiliating Genes
1 hepatitis 30.6 F2 GGT1 GPT SLC17A5 TNF
2 autoimmune hepatitis 30.5 F2 GGT1 GPT
3 iga glomerulonephritis 30.4 ALB IL6 REN
4 cholecystitis 30.4 ALB F2 GPT
5 biliary atresia 30.4 ALB GPT HGF
6 acute pancreatitis 30.3 CRP CXCL8 IL6
7 choledocholithiasis 30.2 ALB ALPP F2 GPT SLC17A5
8 acute cholangitis 30.1 CRP IL6
9 viral hepatitis 30.0 ALB F2 GGT1 GPT SLC17A5 TNF
10 portal hypertension 30.0 ALB EDN1 F2 GPT TNF
11 hepatitis e 30.0 ALB F2 GPT TNF
12 bilirubin metabolic disorder 29.9 ALB F2 GGT1 GPT SLC17A5
13 sclerosing cholangitis 29.9 ALB GGT1 GPBAR1 TNF
14 hepatorenal syndrome 29.8 ALB EDN1 F2 REN
15 fascioliasis 29.8 ALB ALPP GPT SLC17A5
16 monocytic leukemia 29.8 CXCL8 IL6 TNF
17 infantile liver failure syndrome 1 29.8 ALB F2 GPT SLC17A5
18 cholestasis 29.7 ALPP F2 GGT1 GPT SLC25A13
19 opisthorchiasis 29.7 CXCL8 GPT TNF
20 abdominal tuberculosis 29.7 ALB CRP F2
21 deficiency anemia 29.7 ALB CRP IL6
22 kawasaki disease 29.6 ALB CRP IL6 TNF
23 biliary tract disease 29.6 ALB F2 GGT1 GPBAR1 SLC25A13
24 cholangitis, primary sclerosing 29.6 ALB GGT1 GPBAR1 GPT
25 hepatic tuberculosis 29.4 ALB ALPP F2 GGT1 GPT
26 alcoholic liver cirrhosis 29.4 ALB CXCL8 F2 SLC17A5
27 lung disease 29.3 CXCL8 EDN1 IL6 TNF
28 acute cystitis 29.3 ALB CRP CXCL8 IL6
29 fatty liver disease 29.3 CXCL8 GGT1 IL6 SLC17A5 TNF
30 hepatitis b 29.2 ALB F2 GGT1 GPT SLC17A5 TNF
31 myeloma, multiple 29.2 ALB CRP CXCL8 HGF IL6 TNF
32 ulcerative colitis 29.2 CRP CXCL8 IL6 TNF
33 gastroenteritis 29.2 ALB CRP CXCL8 IL6 TNF
34 diabetes mellitus 29.1 ALB CRP EDN1 IL6 REN TNF
35 appendicitis 29.1 ALB CRP CXCL8 IL6 TNF
36 cholangitis 29.0 ALB CRP F2 GGT1 GPBAR1 GPT
37 pyelonephritis 28.8 ALB CRP CXCL8 IL6 TNF
38 liver cirrhosis 28.8 ALB EDN1 F2 GGT1 GPT HGF
39 kidney disease 28.8 ALB CRP EDN1 IL6 REN TTR
40 inflammatory bowel disease 28.8 CRP CXCL8 IL6 TNF
41 peritonitis 28.7 ALB CRP CXCL8 F2 IL6 TNF
42 liver disease 28.7 ALB ALPP F2 GGT1 GPT HGF
43 malaria 28.4 ALB CRP CXCL8 EDN1 IL6 TNF
44 mirizzi syndrome 11.4
45 biliary malformation with renal tubular insufficiency 11.4
46 cholestasis, benign recurrent intrahepatic, 1 11.3
47 acth deficiency, isolated 11.2
48 cholestasis, benign recurrent intrahepatic, 2 11.2
49 bile acid synthesis defect, congenital, 1 11.2
50 congenital disorder of glycosylation, type ik 11.2

Graphical network of the top 20 diseases related to Obstructive Jaundice:



Diseases related to Obstructive Jaundice

Symptoms & Phenotypes for Obstructive Jaundice

UMLS symptoms related to Obstructive Jaundice:


icterus, jaundice (not of newborn)

MGI Mouse Phenotypes related to Obstructive Jaundice:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.85 EDN1 F2 GGT1 GPBAR1 HGF IL6
2 homeostasis/metabolism MP:0005376 9.73 ALB CRP EDN1 F2 GGT1 GPBAR1
3 renal/urinary system MP:0005367 9.23 ALB EDN1 GGT1 GPBAR1 IL6 REN

Drugs & Therapeutics for Obstructive Jaundice

Drugs for Obstructive Jaundice (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lactulose Approved Phase 4 4618-18-2 11333
2
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
3
Ofloxacin Approved Phase 4 82419-36-1 4583
4
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
5 Anti-Infective Agents, Urinary Phase 4
6 Cytochrome P-450 Enzyme Inhibitors Phase 4
7 Antibiotics, Antitubercular Phase 4,Not Applicable
8 Anti-Bacterial Agents Phase 4,Not Applicable
9 Topoisomerase Inhibitors Phase 4
10 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
11 Antitubercular Agents Phase 4
12 Renal Agents Phase 4
13 Anti-Infective Agents Phase 4,Not Applicable
14
Trioxsalen Approved Phase 2, Phase 3,Not Applicable 3902-71-4 5585
15
Ezetimibe Approved Phase 3 163222-33-1 150311
16
Atorvastatin Approved Phase 3 134523-00-5 60823
17
Simvastatin Approved Phase 3 79902-63-9 54454
18
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
19
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
20
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
21
Methionine Approved, Nutraceutical Phase 3 63-68-3 6137
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
23 Dihematoporphyrin Ether Phase 2, Phase 3,Not Applicable
24 Hematoporphyrin Derivative Phase 2, Phase 3,Not Applicable
25 Antimetabolites Phase 3
26 Anticholesteremic Agents Phase 3
27 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
28 Hypolipidemic Agents Phase 3
29 Lipid Regulating Agents Phase 3
30 Calcium, Dietary Phase 3
31 Rosuvastatin Calcium Phase 3 147098-20-2
32 Nicotinic Acids Phase 3
33 Vitamin B3 Phase 3
34 Vitamins Phase 3
35 Pharmaceutical Solutions Phase 3
36 Vitamin B Complex Phase 3
37 Folate Phase 3
38 Micronutrients Phase 3
39 Nutrients Phase 3
40 Vasodilator Agents Phase 3
41 Trace Elements Phase 3
42 Vitamin B9 Phase 3
43
Ursodeoxycholic acid Approved, Investigational Phase 2 128-13-2 31401
44
Neostigmine Approved, Vet_approved Phase 1, Phase 2 59-99-4 4456
45
Pancrelipase Approved, Investigational Phase 2,Phase 1 53608-75-6
46 Gastrointestinal Agents Phase 2
47 Liver Extracts Phase 2,Phase 1
48 Cholagogues and Choleretics Phase 2
49 Cholinergic Agents Phase 1, Phase 2
50 Neurotransmitter Agents Phase 1, Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 Randomised Trial Comparing Metal and Plastic Biliary Stents Stents for Palliating Malignant Jaundice Unknown status NCT00731419 Phase 4
2 Human Kidney Histopathology in Obstructive Jaundice Completed NCT01090193 Phase 4
3 Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents Completed NCT01315522 Phase 4
4 Antibiotics to Decrease Post ERCP Cholangitis Recruiting NCT03087656 Phase 4 Ceftriaxone;Levofloxacin
5 Preoperative Biliary Drainage for the Lower Malignant Obstructive Jaundice Unknown status NCT01744938 Phase 3
6 Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma Unknown status NCT01755013 Phase 2, Phase 3
7 Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block. Completed NCT00391183 Phase 2, Phase 3
8 A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383) Completed NCT02550288 Phase 3 Ezetimibe 10 mg;Atorvastatin 10 mg;Placebo for Ezetimibe 10 mg tablet;Placebo for Atorvastatin 10 mg capsule
9 A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384) Completed NCT02460159 Phase 3 EZ 10 mg/Atorva 20 mg FDC;EZ 10 mg/Atorva 10 mg FDC
10 A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832) Completed NCT02741245 Phase 3 Ezetimibe 10 mg;Rosuvastatin 2.5 mg;Placebo for Ezetimibe;Placebo for Rosuvastatin
11 MK-0524B Lipid Study (MK-0524B-063) Completed NCT00479882 Phase 3 Comparator: simvastatin;MK-0524A;Placebo;MK-0524B
12 Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024) Completed NCT00289900 Phase 3 MK-0524A;Atorvastatin;Simvastatin
13 Remaxol® in Mechanical Jaundice of Non-malignant Origin Recruiting NCT03418935 Phase 3 Remaxol (succinate + methionine + inosine + nicotinamide);Ringer's Solution
14 Remaxol® in Malignant Mechanical Jaundice Recruiting NCT03416062 Phase 3 Remaxol®;Ringer's Solution
15 A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118) Terminated NCT01294683 Phase 3 Simvastatin;Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM);Extended Release (ER) niacin/laropiprant (N/LRPT);Placebo
16 Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction Withdrawn NCT01622803 Phase 3
17 The Effect of Ursodeoxycholic Acid in Liver Functional Restoration of Patients With Obstructive Jaundice Unknown status NCT01688375 Phase 2 Ursodeoxycholic Acid
18 Role of Endoscopic RFA in Prolonging the Patency of Metal Stents in Patients With Malignant Obstructive Jaundice Unknown status NCT01275768 Phase 1, Phase 2
19 Cholinergic Anti-inflammatory Pathway in Prevention & Treatment of the SIRS in Patients With Jaundice After Operation. Unknown status NCT02279147 Phase 1, Phase 2 neostigmine methylsulfate,raceanisodamine hydrochloride
20 Evaluation of Preoperative Biliary Drainage Before Pancreatoduodenectomy Unknown status NCT01941342 Phase 2
21 Metal or Plastic Stents to Relieve Obstruction of Obstructive Jaundice Prior to Resection of Periampullary Tumors. Completed NCT02166840 Phase 2
22 Radiofrequency Ablation for Biliopancreatic Malignancy Completed NCT02468076 Phase 2
23 SMOFlipid to Lessen the Severity of Neonatal Cholestasis Terminated NCT02721277 Phase 1, Phase 2 SMOFlipid
24 C-VISA BikDD: Liposome in Advanced Pancreatic Cancer Withdrawn NCT00968604 Phase 1
25 Immune Function in Patients With Obstructive Jaundice Unknown status NCT01367821
26 Cholangioscopic Assessment of Occluded Biliary Stent and Role of Biliary Radiofrequency Ablation Unknown status NCT03133026 Not Applicable
27 Percutaneous Transhepatic Cholangiography Versus Endoscopic Ultrasound Guided Biliary Drainage Unknown status NCT01686425 Not Applicable
28 Study of Abdominal Drainage in LCBDE+PC Unknown status NCT03120754 Not Applicable
29 Intra-luminal Radiofrequency Ablation for Inoperable Malignant Biliary Stenosis Unknown status NCT02841800 Not Applicable
30 Evaluation of Immune Function in Biliary Atresia Children With Prolonged Jaundice Unknown status NCT00155194
31 Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders Unknown status NCT01438385
32 Application of n-3 Fatty to Patient of Jaundice Completed NCT03376945 trail cohort;control cohort
33 Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers Completed NCT01134276 Not Applicable
34 Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma Completed NCT01506115 Not Applicable Photofrin
35 Endoscopic Versus Percutaneous Drainage For Hilar Block in Gall Bladder Cancer Completed NCT00409864 Not Applicable
36 Outcome of Carbon Dioxide Versus Air Insufflations During Endoscopic Retrograde Cholangiopancreatography (ERCP) Completed NCT01321203
37 Endoscopic Ultrasound-guided Biliary Drainage for Malignant Biliary Obstruction After Failed ERCP Completed NCT03510754
38 Malignant Obstruction ZILVER Against Routine Therapy (MOZART I) Completed NCT00196105 Not Applicable
39 Biliary Atresia, Hepatic Buffer Response and Sevoflurane Completed NCT02471209 Sevoflurane
40 Early Versus Late Cholecystectomy After Clearance of Common Bile Duct Stones Completed NCT02460315 Not Applicable
41 Endoscopic Retrograde Cholangiopancreatography (ERCP) Based Sampling of Indeterminate Bile Duct Strictures Completed NCT01580709 Not Applicable
42 Biliary Cannulation During Endoscopic Retrograde Cholangiopancreatography: Precut Versus Conventional Cannulation Completed NCT02477228 Not Applicable
43 Pre-treatment With Methylene Blue Prevent Peri-operative Reduced Systemic Vascular Resistance Recruiting NCT03406676 Not Applicable Methylene Blue
44 EUS Evaluation of CBD Diameter in Malignant Obstructive Jaundice Recruiting NCT03494023
45 Comparison of Metal and Plastic Stents for Preoperative Biliary Decompression Recruiting NCT01191814 Not Applicable
46 Efficacy of Partial Covered Double Bare Metal Stent Compared to Uncovered Double Bare Metal Stent in Malignant Biliary Obstruction Recruiting NCT02937246 Not Applicable
47 RFA RCT for Pancreatic or Bile Duct Cancer Recruiting NCT02166190 Not Applicable
48 The Necessity of Bile Cultures in Patients With Acute Cholangitis Recruiting NCT02601417 Not Applicable
49 A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction Recruiting NCT02659852 Not Applicable
50 Efficacy and Safety of Endobiliary Radiofrequency Ablation by Using a Novel RF Catheter (ELRA®) on Maintaining the Patency of Endobiliary Metal Drainage in Patients With Malignant Biliary Strictures : A Double-arm Comparable Study Recruiting NCT02646514 Not Applicable

Search NIH Clinical Center for Obstructive Jaundice

Cochrane evidence based reviews: jaundice, obstructive

Genetic Tests for Obstructive Jaundice

Anatomical Context for Obstructive Jaundice

MalaCards organs/tissues related to Obstructive Jaundice:

42
Liver, Pancreas, Kidney, Heart, Testes, Myeloid, Prostate

Publications for Obstructive Jaundice

Articles related to Obstructive Jaundice:

(show top 50) (show all 2303)
# Title Authors Year
1
Peri-Ampullary Metastasis From Endometrial Adenocarcinoma: A Rare Etiology of Obstructive Jaundice. ( 30834033 )
2019
2
Obstructive jaundice caused by an adenoma of the common hepatic duct. ( 29980303 )
2019
3
An unusual case of obstructive jaundice: ampullary Burkitt lymphoma. ( 31032110 )
2019
4
Clonorchiasis sinensis detected by laparoscopic exploration of biliary tracts in two patients with obstructive jaundice. ( 30621611 )
2019
5
Duodenal somatostatinoma presenting as obstructive jaundice with the coexistence of a gastrointestinal stromal tumour in neurofibromatosis type 1: a case with review of the literature. ( 30635305 )
2019
6
EUS-guided versus percutaneous biliary access in patients with obstructive jaundice due to gastric cancer. ( 30327252 )
2019
7
Obstructive jaundice caused by myeloid sarcoma in duodenal ampulla. ( 30253977 )
2019
8
Myeloid sarcoma of the parotid and stomach presenting with obstructive jaundice; a rare presentation ( 30993960 )
2019
9
Primary pancreatic lymphoma as a cause of obstructive jaundice. ( 29615287 )
2019
10
Combined Treatment of Nonresectable Cholangiocarcinoma Complicated by Obstructive Jaundice. ( 30965145 )
2019
11
Spironolactone rescues renal dysfunction in obstructive jaundice rats by upregulating ACE2 expression. ( 29882088 )
2019
12
Obstructive jaundice of a parasitic etiology. ( 30318892 )
2019
13
First report of hepatobiliary Mycobacterium avium infection developing obstructive jaundice in a patient with neutralizing anti-interferon-gamma autoantibodies. ( 30505452 )
2019
14
Transhepatic forceps biopsy combined with biliary drainage in obstructive jaundice: safety and accuracy. ( 30511177 )
2019
15
Safety of Percutaneous Transhepatic Biliary Stenting in Patients with Obstructive Jaundice. ( 30630564 )
2019
16
The Application of Intravoxel Incoherent Motion Diffusion-Weighted Imaging in the Diagnosis of Hilar Obstructive Jaundice. ( 30664118 )
2019
17
Huge Intramural Duodenal Hematoma Complicated with Obstructive Jaundice following Endoscopic Hemostasis. ( 30690957 )
2019
18
Biliary Ascariasis: An Unusual Case of Obstructive Jaundice. ( 30710698 )
2019
19
Bile Cast Nephropathy in a Patient With Obstructive Jaundice. ( 30775631 )
2019
20
Effects of different drainage methods on serum bile acid and hepatocyte apoptosis and regeneration after partial hepatectomy in rats with obstructive jaundice. ( 30971329 )
2019
21
A prospective study of risk factors for in-hospital mortality in patients with malignant obstructive jaundice undergoing percutaneous biliary drainage. ( 30985679 )
2019
22
Endoscopic Ultrasound-Guided Biliary Drainage for Palliation of Malignant Obstructive Jaundice. ( 31011304 )
2019
23
CholedochoClip: A Case of Obstructive Jaundice 14 Years after Cholecystectomy. ( 31016053 )
2019
24
A Simple and Easily Reproducible Model of Reversible Obstructive Jaundice in Rats. ( 31028186 )
2019
25
Unusual Case of Obstructive Jaundice. ( 31032154 )
2019
26
Giant choledochal cyst. An unusual cause of obstructive jaundice in an adult. ( 31104867 )
2019
27
Autoimmune Hemolytic Anemia Obscured by the Obstructive Jaundice Associated with IgG4-related Sclerosing Cholangitis in a Patient with Type 1 Autoimmune Pancreatitis: A Case Report and Review of the Literature. ( 29269682 )
2018
28
Immunoglobulin G4 Sclerosing Cholangitis: An Unusual Cause of Obstructive Jaundice-Case Report and Literature Review. ( 30210896 )
2018
29
Eosinophilic Gastroenteritis in Which Obstructive Jaundice Developed due to Invagination of the Duodenal Wall. ( 29434146 )
2018
30
Obstructive Jaundice due to Pancreatic Involvement as an Initial Presentation of Adult Acute Lymphoblastic Leukemia. ( 30627461 )
2018
31
Duodenal mucinous adenocarcinoma presenting as ileus, obstructive jaundice and massive ascites: A case report. ( 29456851 )
2018
32
Obstructive Jaundice due to Primary Neurofibroma of the Common Bile Duct. ( 30606373 )
2018
33
Advanced Roux-en-Y hepaticojejunostomy with magnetic compressive anastomats in obstructive jaundice dog models. ( 28779259 )
2018
34
A Systematic Review and Meta-analysis of Intraluminal Brachytherapy Versus Stent Alone in the Treatment of Malignant Obstructive Jaundice. ( 29075881 )
2018
35
MicroRNA-29a mitigation of endoplasmic reticulum and autophagy aberrance counteracts in obstructive jaundice-induced fibrosis in mice. ( 29105510 )
2018
36
Evaluation of liver function by means of serum cytokeratin 18 and hepatocyte growth factor levels in patients with obstructive jaundice. ( 29258405 )
2018
37
Efficacy of 125I Versus Non-125I Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice. ( 29305738 )
2018
38
MicroRNA-29a mitigation of toll-like receptor 2 and 4 signaling and alleviation of obstructive jaundice-induced fibrosis in mice. ( 29366780 )
2018
39
Hepatobiliary and Pancreatic: Rare cause of obstructive jaundice by Trichosporon asahii. ( 29372610 )
2018
40
Pathophysiological consequences of obstructive jaundice and perioperative management. ( 29428098 )
2018
41
Obstructive jaundice as primary presentation of a stage IIE Non-Hodgkin lymphoma: A decision making process between advanced lymphoma and locally advanced/metastatic pancreatic adenocarcinoma. ( 29547849 )
2018
42
The Effect of Calcium Dobesilate on Liver Damage in Experimental Obstructive Jaundice. ( 29589984 )
2018
43
A Surgically Resected Pancreatic Schwannoma with Obstructive Jaundice with Special Reference to Differential Diagnosis from Other Cystic Lesions in the Pancreas. ( 29606941 )
2018
44
Comparison of Endoscopic Ultrasonography Guided Biliary Drainage and Percutaneous Transhepatic Biliary Drainage in the Management of Malignant Obstructive Jaundice After Failed ERCP: Erratum. ( 29613967 )
2018
45
Pancreatic Burkitt's lymphoma presenting as an unusual cause of obstructive jaundice. ( 29696783 )
2018
46
Malignant obstructive jaundice treated with intraluminal placement of Iodine-125 seed strands and metal stents: An analysis of long-term outcomes and prognostic features. ( 29748084 )
2018
47
Safety and efficacy of irreversible electroporation in the treatment of obstructive jaundice in advanced hilar cholangiocarcinoma. ( 30057125 )
2018
48
Adenosquamous Carcinoma of the Ampulla of Vater: A Rare Cause of Obstructive Jaundice. ( 29998166 )
2018
49
A patient with abdominal pain and obstructive jaundice. ( 29749334 )
2018
50
Post-operative care of interventional therapy for 40 liver cancer patients with obstructive jaundice. ( 29767833 )
2018

Variations for Obstructive Jaundice

Expression for Obstructive Jaundice

Search GEO for disease gene expression data for Obstructive Jaundice.

Pathways for Obstructive Jaundice

Pathways related to Obstructive Jaundice according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.09 CXCL8 HGF IL6 TNF
2
Show member pathways
12 CXCL8 EDN1 IL6 TNF
3
Show member pathways
11.97 ALB CRP F2 GGT1 IL6 TNF
4 11.84 CXCL8 IL6 TNF
5 11.83 ALB ALPP HGF IL6
6 11.78 EDN1 IL6 TNF
7 11.73 CXCL8 HGF IL6 TNF
8 11.72 CXCL8 IL6 TNF
9 11.68 CXCL8 IL6 TNF
10 11.62 CXCL8 EDN1 IL6 TNF
11 11.59 CXCL8 IL6 TNF
12
Show member pathways
11.5 CXCL8 IL6 TNF
13 11.43 CXCL8 IL6 TNF
14 11.34 CXCL8 IL6 TNF
15 11.25 ALB F2 TTR
16 11.25 CXCL8 HGF IL6 TNF
17 11.03 CXCL8 HGF IL6 TNF
18 10.82 CXCL8 EDN1 HGF IL6 TNF
19 10.54 CRP CXCL8 IL6 TNF

GO Terms for Obstructive Jaundice

Cellular components related to Obstructive Jaundice according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 ALB CRP CXCL8 EDN1 F2 HGF
2 extracellular space GO:0005615 9.4 ALB CRP CXCL8 EDN1 F2 GGT1

Biological processes related to Obstructive Jaundice according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.73 CXCL8 HGF IL6 TNF
2 cellular protein metabolic process GO:0044267 9.67 ALB F2 IL6 TTR
3 positive regulation of DNA-binding transcription factor activity GO:0051091 9.65 EDN1 IL6 TNF
4 defense response to Gram-positive bacterium GO:0050830 9.63 CRP IL6 TNF
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.58 F2 HGF TNF
6 embryonic digestive tract development GO:0048566 9.51 CXCL8 TNF
7 positive regulation of glial cell proliferation GO:0060252 9.49 IL6 TNF
8 positive regulation of smooth muscle cell proliferation GO:0048661 9.43 EDN1 IL6 TNF
9 acute-phase response GO:0006953 9.33 CRP F2 IL6
10 positive regulation of neuroinflammatory response GO:0150078 9.32 IL6 TNF
11 regulation of signaling receptor activity GO:0010469 9.17 CXCL8 EDN1 F2 HGF IL6 TNF
12 negative regulation of lipid storage GO:0010888 9.13 CRP IL6 TNF

Molecular functions related to Obstructive Jaundice according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.43 ALB CRP HGF SLC25A13 TNF TTR
2 cytokine activity GO:0005125 8.92 CXCL8 EDN1 IL6 TNF

Sources for Obstructive Jaundice

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....